Teva director exercises 14,492 share units
Teva Pharmaceutical Industries director Chen Lichtenstein exercised 14,492 restricted share units into ordinary shares, increasing his direct stake to 19,296 shares.
Rhea-AI Filing Summary
Teva Pharmaceutical Industries director Chen Lichtenstein exercised 14,492 restricted share units into ordinary shares, increasing his direct stake to 19,296 shares. The units were granted on June 5, 2025 and vested on June 5, 2026, and each unit settled into one ordinary share at no cash cost to him.
The ordinary shares may be held directly or represented by American Depositary Shares, each currently equal to one ordinary share. The filing reflects a compensation-related equity vesting and exercise, not an open-market purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Share Units | 14,492 | $0.00 | $0.00 |
| Exercise | Ordinary Shares | 14,492 | $0.00 | $0.00 |
Footnotes (3)
- F1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- F3. Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.
Key Figures
Key Terms
Exercise or conversion of derivative security financial
contingent right financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Teva (TEVA) director Chen Lichtenstein report?
AI-generated analysis. How Rhea-AI works. Not financial advice.